证券代码：688046 证券简称：药康生物 公告编号：2023-054 江苏集萃药康生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 江苏集萃药康生物科技股份有限公司（以下简称"公司"）于 2023 年 8 月 31 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度经营成果、财务状况，公司计划于 2023 年 10 月 10 日 下午 16:00- 17:00 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 会议召开时间：2023 年 10 月 10 日(星期二) 下午 16:00-17:00 会议召开地点：上海证券交易所上证路演中心（网址： 会议召开方式：上证路演中心网 ...

华泰联合证券有限责任公司 关于江苏集萃药康生物科技股份有限公司 2023 年半年度持续督导跟踪报告 保荐机构名称：华泰联合证券有限责任公司 被保荐公司简称：江苏集萃药康生物科技股 份有限公司 保荐代表人姓名：季李华 联系电话：010-56839300 保荐代表人姓名：洪捷超 联系电话：010-56839300 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐机构"）作为江苏集萃药康生物科技股份有限 公司（以下简称"药康生物"、"公司"或"发行人"）首次公开发行股票的保 荐机构，对药康生物进行持续督导，并出具本 2023 年半年度持续督导跟踪报告： 一、保荐机构和保荐代表人发现的问题及整改情况 截至2023年6月30日，公司募投项目"模式动物小鼠研发繁育一体化基地建 设项目"和"真实世界动物模型研发及转化平台建设项目"的项目建设进度晚于 预期；公司前期已经公告说明了相关情况及原因。保荐机构督促公司加快推进募 投项目建设进度，进一步提高募资资金使用效率，并且同时做好信息披露。 此外，保荐机构建 ...

特此公告。 证券代码：688046 证券简称：药康生物 公告编号：2023-053 江苏集萃药康生物科技股份有限公司（以下简称"公司"）董事会近日收 到公司财务总监焦晓杉先生的书面辞职报告。焦晓杉先生因个人原因申请辞去 财务总监职务，辞任后不再担任公司任何职务，根据《公司法》《公司章程》 等有关规定，辞职报告自送达公司董事会之日起生效。公司及公司董事会对焦 晓杉先生任职期间为公司发展所做的贡献表示衷心感谢。 为保证公司各项工作的正常开展，公司将按照《上海证券交易所科创板股 票上市规则》《公司章程》等相关规定，尽快完成新任财务总监的选聘工作。 江苏集萃药康生物科技股份有限公司 关于公司财务总监辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏集萃药康生物科技股份有限公司董事会 2023 年 9 月 9 日 1 ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2023, representing a 20% increase compared to the same period last year[1]. - The company's operating revenue for the first half of 2023 was approximately ¥295.86 million, representing an 18.17% increase compared to ¥250.37 million in the same period last year[23]. - The net profit attributable to shareholders for the reporting period was approximately ¥77.57 million, a decrease of 4.98% from ¥81.64 million in the previous year[22]. - The basic earnings per share for the first half of 2023 was ¥0.19, down 13.64% from ¥0.22 in the same period last year[21]. - The net profit after deducting non-recurring gains and losses was approximately ¥49.53 million, a decrease of 8.99% from ¥54.42 million in the previous year[22]. - The net cash flow from operating activities increased by 18.42% to approximately ¥26.21 million, up from ¥22.14 million in the previous year[22]. - The total assets at the end of the reporting period were approximately ¥2.40 billion, reflecting a 6.51% increase from ¥2.25 billion at the end of the previous year[23]. - The weighted average return on net assets decreased to 3.85%, down 3.14 percentage points from 6.99% in the previous year[21]. - Financial guidance for the upcoming quarters suggests continued growth, driven by new product launches and increased market penetration[14]. Research and Development - Research and development expenses increased by 30% to RMB 150 million, reflecting the company's commitment to innovation[1]. - The total R&D expenditure for the reporting period was approximately ¥50.46 million, representing a 30.68% increase compared to the previous year, driven by ongoing large-scale R&D projects and an expanded R&D team[79]. - R&D expenditure as a percentage of operating income increased from 15.42% to 17.05% year-on-year[80]. - The company is focused on developing innovative mouse models for research and drug development, leveraging technologies such as gene editing and stem cell research[27]. - The company aims to establish a comprehensive range of knockout mouse strains through its "Spotted Mouse Project," targeting over 20,000 protein-coding genes for commercialization[28]. - The company has developed core technologies including gene-engineered mouse model construction and innovative drug screening platforms, protected by patents and trade secrets[60]. - The company has launched two new mouse models, the 750 Fat Mouse and the 765 Smart Mouse, with the former showing better efficacy in lipid-lowering and fatty liver treatment compared to existing models[69]. - The company has developed a reliable liver injury mouse model with low mortality rates in offspring, facilitating research on liver diseases[64]. Market Expansion - The company expects revenue guidance for the second half of 2023 to be between RMB 600 million and RMB 700 million, indicating a projected growth of 25% to 40%[1]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[1]. - The overseas market generated revenue of 42.88 million yuan, accounting for 14.49% of total revenue, with a year-on-year growth of 72.41%[95]. - The company is actively pursuing market expansion strategies, aiming to enhance its product offerings and reach new customer segments[14]. - The company is enhancing its international presence by participating in nearly 20 international academic conferences and increasing its marketing efforts abroad[95]. Compliance and Governance - The company has no significant non-operating fund occupation by controlling shareholders or related parties[1]. - There are no violations of decision-making procedures regarding external guarantees[1]. - The board of directors confirmed that all members attended the meeting, ensuring governance compliance[1]. - The company maintains a strong commitment to compliance and ethical standards in its research practices, ensuring the integrity of its scientific contributions[12]. - The company emphasizes the importance of governance and the protection of minority shareholders' rights in its governance structure[175]. Innovation and Technology - Future outlook includes the development of new products and technologies, leveraging CRISPR/Cas9 gene editing techniques to advance its research capabilities[13]. - The company has established the largest gene-engineered mouse resource library globally, with over 21,000 mouse strains and an annual model creation capacity exceeding 6,000[58]. - The company has implemented advanced techniques in mouse breeding and genetic monitoring to enhance the quality of its mouse models[65]. - The company has developed a high-efficiency aseptic animal transport device to ensure the safety and sterility of mice during transit[64]. - The company is focusing on expanding its portfolio of gene editing technologies, including CRISPR Cas9 applications for various genetic modifications[62]. Environmental Responsibility - The company has established an environmental protection mechanism and invested 1.325 million yuan in environmental protection during the reporting period[144]. - The company has a good compliance record in environmental management and has not faced any administrative penalties for environmental issues[145]. - The company promotes sustainable development through energy-saving management policies and encourages green office practices, such as reducing paper consumption and promoting water conservation[149]. Shareholder Commitments - The actual controller Gao Xiang commits to not transferring or entrusting the management of shares held before the IPO for 36 months post-listing[154]. - The controlling shareholder Nanjing Laoyan also commits to a 36-month lock-up period for shares held before the IPO[157]. - Shareholders holding more than 5% of the company commit to a 12-month lock-up period for shares held before the IPO[161]. - The company plans to strictly adhere to relevant laws and regulations regarding share reduction after the lock-up period[158]. - The company will ensure that any share reduction plans are made cautiously to stabilize stock prices and support daily operations[158].

核查意见 华泰联合证券有限责任公司 关于江苏集萃药康生物科技股份有限公司 首次公开发行部分限售股上市流通的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"） 作为江苏集萃药康生物科技股份有限公司（以下简称"药康生物"或"公司"） 首次公开发行股票并在科创板上市持续督导阶段的保荐机构，根据《证券发行上 市保荐业务管理办法》《科创板上市公司持续监管办法（试行）》《上海证券交易 所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号 ——规范运作》等有关规定，对药康生物首次公开发行部分限售股上市流通事项 进行了认真、审慎的核查，并发表本核查意见，具体情况如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2022 年 3 月 15 日出具的《关于同意江苏集 萃药康生物科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕 542 号），同意公司首次公开发行股票的注册申请。公司首次向社会公众公开发 行人民币普通股（A 股）股票 5,000.00 万股，并于 2022 年 4 月 25 日在上海证券 交易所科创板上市，发行完成后总股本为 410, ...

证券代码：688046 证券简称：药康生物 公告编号：2023-048 江苏集萃药康生物科技股份有限公司 关于首次公开发行部分限售股上市流通的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次上市流通的限售股份数量为 42,545,454 股，限售期为自取得公司股 份之日起 36 个月。 公司首次公开发行部分限售股 12,174,545 股已于 2023 年 8 月 14 日起上市 流通，占目前公司总股本（41,000.00 万股）的 2.97%，限售股股东数量为 1 名。 具体内容请见公司于 2023 年 8 月 5 日在上海证券交易所网站（www.sse.com.cn） 披露的《江苏集萃药康生物科技股份有限公司关于首次公开发行部分限售股上市 流通的公告》（公告编号：2023-039）。 本次上市流通的限售股为公司部分首次公开发行前股东持有的限售股，涉及 股东 9 名，股份数量为 42,545,454 股，占公司股份总数的 10.38%，限售期为自 取得公司股份之日起 36 个月。将于 2023 ...

证券代码：688046 证券简称：药康生物 公告编号：2023-047 江苏集萃药康生物科技股份有限公司 股东集中竞价减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 截至本公告披露日，青岛国药大创投资合伙企业（有限合伙）（以下简称"青 岛国药"）持有江苏集萃药康生物科技股份有限公司（以下简称"公司"或"药 康生物"）股份 26,586,678 股，占公司总股本 6.4846%。上述股份来源均为公司 首次公开发行股票并上市前持有的股份，且已于 2023 年 4 月 25 日解除限售并上 市流通。 集中竞价减持计划的主要内容 公司于近日收到青岛国药送达的《关于集中竞价减持股份计划的告知函》， 因自身资金需求，青岛国药拟减持不超过 3,900,000 股，即不超过公司总股本的 0.95%。其中，在任意连续 90 日内通过集中竞价交易方式减持公司股份的数量不 超过公司股份总数的 1.00%，减持期间为自本公告披露之日起 15 个交易日后的 三个月内。减持期间，若公 ...

证券代码：688046 证券简称：药康生物 公告编号：2023-032 江苏集萃药康生物科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩暨现金 分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 江苏集萃药康生物科技股份有限公司（以下简称"公司"）于 2023 年 4 月 20 日发布公司 2022 年度报告，于 2023 年 4 月 28 日发布公司 2023 年一季度报告， 为便于广大投资者更全面深入地了解公司 2022 年度及 2023 年一季度经营成果、 财务状况，公司计划于 2023 年 06 月 29 日 下午 15:00-16:00 举行 2022 年度暨 2023 年第一季度业绩暨现金分红说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度及 2023 年第 一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 会议 ...

2023 年第一季度报告 证券代码：688046 证券简称：药康生物 江苏集萃药康生物科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同 期增减变动幅度(%) | | --- | --- | --- | | 营业收入 | 140,304,915.96 | 20.82 | | 归属于上市公司股东的净利润 | 31,050,205.03 | 2.39 | | 归属于上市公司股东的扣除非 经常性损益的净利润 | 22,257,363.18 | 2.35 | | 经营 ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the fiscal year 2022, representing a year-over-year growth of 15%[16]. - The company's operating revenue for 2022 was approximately ¥516.55 million, representing a year-on-year increase of 31.17%[23]. - The net profit attributable to shareholders for 2022 was approximately ¥164.64 million, up 31.79% compared to the previous year[23]. - The net profit after deducting non-recurring gains and losses for 2022 was approximately ¥102.06 million, reflecting a 32.16% increase year-on-year[23]. - The company's total assets at the end of 2022 reached approximately ¥2.25 billion, a 113.74% increase from the previous year[24]. - The basic earnings per share for 2022 was ¥0.42, a 20% increase compared to ¥0.35 in 2021[25]. - The company's net assets attributable to shareholders increased by 151.73% year-on-year, reaching approximately ¥1.98 billion[24]. - The gross margin for the year was reported at 60%, an increase from 55% in the previous year, indicating improved operational efficiency[16]. - The company achieved total revenue of 516.55 million yuan in 2022, representing a year-on-year growth of 31.17%[35]. - The gross profit margin for the main business was 71.45%, higher than comparable companies in the industry[124]. - The company reported a total revenue of 66,569 million RMB for the year, with a significant increase in R&D personnel from 122 to 183, representing 13.64% of the total workforce[100][103]. Research and Development - Multiple key R&D projects are underway, indicating a strong focus on innovation and product development[5]. - The company plans to increase its R&D budget by 30% in 2023, aiming to accelerate the development of next-generation therapies[16]. - The total R&D expenditure for the year was approximately ¥82.93 million, representing a 50.23% increase from the previous year[94]. - R&D expenditure as a percentage of operating income increased to 16.05% from 14.02% year-on-year[94]. - The company has developed a variety of genetically modified mouse models, including knockout and humanized models, to meet high market demand[47]. - The company has established a gene-engineered mouse model platform, an innovative drug screening and phenotypic analysis platform, and a germ-free mouse and microbiota colonization platform[75]. - The company is developing next-generation mouse models to better simulate human physiological and pathological conditions, aiming to reduce the gap between preclinical and clinical trial results[74]. - The company has developed a new generation of mouse models, including the "Drug Screening Mouse" and "Germ-Free Mouse," aimed at covering most druggable targets and enhancing product offerings[106][107]. - The company has established partnerships with three leading universities to foster innovation and research collaboration[198]. Market Expansion - The company is currently in a rapid development phase with ongoing construction of three bases in Beijing, Guangdong, and Shanghai, and a North American production base in the planning stage[5]. - The company is expanding its market presence in Europe, aiming to establish partnerships with at least five new distributors by the end of 2023[16]. - The company is actively expanding into overseas markets, which may be impacted by changes in international political and economic conditions[131]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[200]. - The company aims to enhance its overseas market presence, with a focus on North America, by expanding its BD team and establishing a production and service system in the U.S.[178]. - The company plans to enter two new international markets by the end of the next fiscal year, aiming for a 5% contribution to overall revenue[198]. Governance and Financial Management - The board of directors and management have confirmed the accuracy and completeness of the annual report, ensuring transparency for investors[4]. - There are no non-operating fund occupations by controlling shareholders or related parties, indicating sound financial governance[9]. - The company has received a standard unqualified audit report from its accounting firm, reinforcing the reliability of its financial statements[5]. - The company emphasizes governance and operational efficiency, aiming to improve decision-making processes and reduce costs through comprehensive budget management[181]. - The company has established a governance structure in compliance with relevant laws and regulations, enhancing operational efficiency and protecting investor rights[183]. - The total remuneration for the chairman and core technical personnel was reported at 176.78 million yuan for the period[190]. Strategic Acquisitions - A strategic acquisition of a biotech firm was completed, enhancing the company's R&D capabilities and adding two new therapeutic platforms[16]. - The company plans to pursue strategic acquisitions to enhance its product portfolio and market presence[192]. - A strategic acquisition was completed in Q4 2022, enhancing the company's product portfolio and expected to contribute an additional 100 million in revenue annually[200]. User Engagement and Customer Base - User data indicates an increase in active users by 25% compared to the previous year, reaching a total of 500,000 active users[16]. - User data showed a significant increase in revenue, achieving a total of 1.5 billion yuan for the fiscal year, representing a 20% year-over-year growth[198]. - Customer satisfaction ratings improved to 90%, up from 85% in the previous year, indicating enhanced service quality[200]. Risks and Challenges - The company acknowledges a significant short-term funding requirement due to ongoing investments in overseas market expansion and R&D projects[5]. - The company faces risks related to the potential loss of core technical personnel, which could hinder its R&D and operational capabilities[113]. - The company has a non-exclusive license agreement with Broad for CRISPR/Cas9 technology, but the uncertainty of continued authorization poses a risk to its operations[115]. - The company reported a good overall collection situation for accounts receivable, but future adverse changes in client operations could lead to bad debt risks[122]. Sustainability Initiatives - The company is focusing on sustainability initiatives, allocating 57.74 million towards eco-friendly practices[192]. - The management team emphasized a commitment to sustainability, with plans to invest 100 million yuan in eco-friendly technologies[198].